Patents by Inventor Charles GUERIN
Charles GUERIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240182422Abstract: A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: March 23, 2022Publication date: June 6, 2024Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme DENIS, Fabien DE BLASIO, Thierry BOYER, Charles GUERIN, Julien MICHAUX, Romain NAJMAN, Florence MAHUTEAU-BETZER
-
Patent number: 11872206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: July 1, 2022Date of Patent: January 16, 2024Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11617735Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: April 4, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11576890Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: February 26, 2021Date of Patent: February 14, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 11559509Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: June 28, 2022Date of Patent: January 24, 2023Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220409568Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: December 29, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220378736Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: July 1, 2022Publication date: December 1, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20220362206Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: June 28, 2022Publication date: November 17, 2022Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20210236455Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: February 26, 2021Publication date: August 5, 2021Applicant: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Patent number: 10987337Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: GrantFiled: December 16, 2019Date of Patent: April 27, 2021Assignee: Tremeau Pharmaceuticals, Inc.Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
-
Publication number: 20200206182Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.Type: ApplicationFiled: December 16, 2019Publication date: July 2, 2020Inventors: Bradford C. SIPPY, Raymond SKWIERCZYNSKI, Jean-Marie SCHNEIDER, Simon H. DROUIN, Charles GUERIN
-
Patent number: 4643384Abstract: A studio easel for selective tension or compression clamping of a canvas painting stretcher frame having top and bottom cross bars in fixed upright position at a desired level has a pair of elongated channel tracks for mounting upright in laterally spaced relation on a studio wall with a pair of opposed shoes slidable in each track. Grip locks on the shoes secure them to their tracks, a stretcher frame support on one shoe of each pair engages a cross bar of the frame. A push-pull clamp on the other shoe of the pair engages the opposite cross bar of the stretcher frame. The shoes are mounted for stretch clamping the frame by positioning the frame support shoe above the push-pull clamp shoes, hanging the top cross bar of the frame on the support shoes, engaging the bottom support frame with the push-pull clamps and pulling the clamps to stretch the frame.Type: GrantFiled: January 3, 1986Date of Patent: February 17, 1987Inventor: Charles A. Guerin